Abstract
DTA0100 is a new catalytic inhibitor of the human DNA topoisomerase IIα that induces G2/M phase cell cycle arrest in human solid tumor cells lines from various malignancies. In our study, we investigated the effectiveness of the combined treatment of ionizing radiation with DTA0100 on the survival of three representative human solid tumor cell lines: HeLa (cervix), WiDr (colon) and SW1573 (non-small cell lung cancer). The concomitant treatment of DTA0100 and irradiation showed a synergistic and antagonistic effect in the three cell lines tested. A synergistic cytotoxic effect of the combination of DTA0100 and radiation was confirmed by the median drug effect analysis method. It was found that in those protocols where the drug was administered after radiation the most synergistic effect was achieved. Our study constitutes the first in vitro evidence for synergistic effects between DTA0100 and radiation. This combination therapy might thus be expected to be more effective than either treatment alone in patients with cervical, colon and non-small cell lung cancer cells.
Keywords: Anticancer drugs, Antiproliferative, Cancer, Catalytic inhibitor, Cell lines, Chemoradiotherapy, Chemotherapy, DNA, Drug combinations, Mechanism of action, Median drug effect, Mitosis, Radiation therapy, Screening, Topoisomerase
Anti-Cancer Agents in Medicinal Chemistry
Title:In Vitro Synergistic Interaction between DTA0100 and Radiation in Human Cancer Cell Lines
Volume: 12 Issue: 8
Author(s): Elisa Bordon, Leticia G. Leon, Carla Rios-Luci, Pedro C. Lara and Jose M. Padron
Affiliation:
Keywords: Anticancer drugs, Antiproliferative, Cancer, Catalytic inhibitor, Cell lines, Chemoradiotherapy, Chemotherapy, DNA, Drug combinations, Mechanism of action, Median drug effect, Mitosis, Radiation therapy, Screening, Topoisomerase
Abstract: DTA0100 is a new catalytic inhibitor of the human DNA topoisomerase IIα that induces G2/M phase cell cycle arrest in human solid tumor cells lines from various malignancies. In our study, we investigated the effectiveness of the combined treatment of ionizing radiation with DTA0100 on the survival of three representative human solid tumor cell lines: HeLa (cervix), WiDr (colon) and SW1573 (non-small cell lung cancer). The concomitant treatment of DTA0100 and irradiation showed a synergistic and antagonistic effect in the three cell lines tested. A synergistic cytotoxic effect of the combination of DTA0100 and radiation was confirmed by the median drug effect analysis method. It was found that in those protocols where the drug was administered after radiation the most synergistic effect was achieved. Our study constitutes the first in vitro evidence for synergistic effects between DTA0100 and radiation. This combination therapy might thus be expected to be more effective than either treatment alone in patients with cervical, colon and non-small cell lung cancer cells.
Export Options
About this article
Cite this article as:
Bordon Elisa, G. Leon Leticia, Rios-Luci Carla, C. Lara Pedro and M. Padron Jose, In Vitro Synergistic Interaction between DTA0100 and Radiation in Human Cancer Cell Lines, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (8) . https://dx.doi.org/10.2174/187152012802650057
DOI https://dx.doi.org/10.2174/187152012802650057 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Hydrogels Applied in Photodynamic Therapy
Current Medicinal Chemistry Recent Advances for the Synthesis of Selenium-containing Small Molecules as Potent Antitumor Agents
Current Medicinal Chemistry Molecular Modeling of Peptide Derivatives NS3 Protease Inhibitors of the Type 2 Dengue Virus
Current Physical Chemistry The Hsp32 Inhibitors SMA-ZnPP and PEG-ZnPP Exert Major Growth-Inhibitory Effects on CD34+/CD38+ and CD34+/CD38- AML Progenitor Cells
Current Cancer Drug Targets Editorial (Thematic Issue: New Insights into a Classical Pathway: Key Roles of the Mevalonate Cascade in Different Diseases (Part I))
Current Molecular Pharmacology Application of Electroporation in DNA Vaccination Protocols
Current Gene Therapy Development Course and an Application Strategy for Induced Pluripotent Stem Cells in Regenerative Medicine
Current Stem Cell Research & Therapy Increasing Sensitivity to Radiotherapy and Chemotherapy by Using Novel Biological Agents that Alter the Tumor Microenvironment
Current Molecular Medicine Chemoprevention Strategies for High Risk Women
Current Women`s Health Reviews Gene Expression Signatures of Lymph Node Metastasis in Oral Cancer: Molecular Characteristics and Clinical Significances
Current Cancer Therapy Reviews Stem Cell Based Preclinical Drug Development and Toxicity Prediction
Current Pharmaceutical Design Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery Synthesis and Cytotoxic Activity of New β-Carboline Derivatives
Mini-Reviews in Medicinal Chemistry Induction of CYP1A1. The AhR / DRE Paradigm Transcription, Receptor Regulation, and Expanding Biological Roles
Current Drug Metabolism Advances in Antioxidative Therapy of Multiple Sclerosis
Current Medicinal Chemistry A Comprehensive Review on Pharmacognostical Investigation and Pharmacology of Typhonium trilobatum
The Natural Products Journal Ceramide: Therapeutic Potential in Combination Therapy for Cancer Treatment
Current Drug Metabolism Herpes Simplex Virus Vectors for the Nervous System
Current Gene Therapy Dual Function of Nitric Oxide in Carcinogenesis, Reappraisal
Current Drug Metabolism Mechanisms of Cytotoxicity of Anticancer Titanocenes
Anti-Cancer Agents in Medicinal Chemistry